A share price of Keros Therapeutics Inc [KROS] is currently trading at $62.18, up 2.96%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KROS shares have gain 7.26% over the last week, with a monthly amount glided 12.97%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on September 23, 2024, and set its price target to $96. On June 25, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $102 on the stock. William Blair started tracking the stock assigning a Outperform rating. Wells Fargo initiated its recommendation with a Overweight and recommended $60 as its price target on December 08, 2023. Wedbush started tracking with a Outperform rating for this stock on July 31, 2023, and assigned it a price target of $86. In a note dated July 26, 2023, BofA Securities initiated an Buy rating and provided a target price of $65 on this stock.
Keros Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $27.02 and $73.00. Currently, Wall Street analysts expect the stock to reach $102 within the next 12 months. Keros Therapeutics Inc [NASDAQ: KROS] shares were valued at $62.18 at the most recent close of the market. An investor can expect a potential return of 64.04% based on the average KROS price forecast.
Analyzing the KROS fundamentals
Gross Profit Margin for this corporation currently stands at -4.1% with Operating Profit Margin at -696.15%, Pretax Profit Margin comes in at -620.13%, and Net Profit Margin reading is -620.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.45 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 60.35 points at the first support level, and at 58.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 63.27, and for the 2nd resistance point, it is at 64.35.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Keros Therapeutics Inc [NASDAQ:KROS] is 20.37. Further, the Quick Ratio stands at 20.37, while the Cash Ratio is 19.1. Considering the valuation of this stock, the price to sales ratio is 8640.72, the price to book ratio is 5.34.
Transactions by insiders
Recent insider trading involved GORDON CARL L, Director, that happened on Aug 13 ’24 when 0.25 million shares were sold. Director, ORBIMED ADVISORS LLC completed a deal on Aug 13 ’24 to sell 0.25 million shares. Meanwhile, Shareholder OrbiMed Genesis Master Fund, L bought 29400.0 shares on Aug 13 ’24.
